By Doug Macron

Roche this week said it will shut down its in-house RNAi-related research activities as part of a broader cost-savings initiative that will include cutting its workforce by 6 percent over the next two years.

The company, which had been one of a handful of big pharmas to invest heavily in RNAi as a therapeutic modality, said it is responding to "mounting cost pressures in healthcare" and to "increasing hurdles for the approval and pricing of new medicines."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.